Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 5
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 (emricasan) in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases
Nonalcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Enrolment: 38 · Results not recorded
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 (emricasan) in Subjects With Liver Cirrhosis
Liver Cirrhosis · Hepatic Cirrhosis
Enrolment: 87 · Results not recorded
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 (emricasan) in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy
Alcoholic Hepatitis
Enrolment: 5 · Results not recorded
Companion Protocol for the 13C-Methacetin Breath Test for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17
Decompensated Cirrhosis
Enrolment: 199 · Results not recorded
Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo
Liver Diseases · Liver Fibrosis · Liver Cirrhosis · NASH Fibrosis
Enrolment: 40 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatTBIUnspecifiedSprague-Dawleyn = Human cohort: 24,585 with TBI and 122,925 without TBI; anim…Intracranial administrationAfter traumatic brain injury
Model: Rat traumatic brain injury model, paired with a population-based cohort study of 24,585 patients with TBI and 122,925 without
TBI was associated with a higher risk of frontotemporal dementia in humans (adjusted hazard ratio 4.43, 95% CI 3.85 to 5.10) and produced FTD-like behavioural impairments in rats linked to TDP-43 short fragment mislocalisation; the abstract does not state the magnitude of benefit from the caspase-3…
Extraction: extract · Supplied extraction confidence: 0.4. Machine-extracted fields require source verification.
